Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs Bromocriptine in hyperprolactinemia
NCT07124221Phase 3Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabergoline in hyperprolactinemia, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
cabergoline
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on NCT07124221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124221.